X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (22946) 22946
Publication (1978) 1978
Book Chapter (125) 125
Book Review (95) 95
Conference Proceeding (48) 48
Dissertation (38) 38
Magazine Article (11) 11
Paper (8) 8
Book / eBook (5) 5
Data Set (2) 2
Government Document (1) 1
Reference (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (7901) 7901
humans (6393) 6393
index medicus (5604) 5604
dipeptides - pharmacology (5062) 5062
male (4085) 4085
dipeptides - chemistry (3557) 3557
dipeptides (3547) 3547
biochemistry & molecular biology (3379) 3379
rats (3109) 3109
dipeptides - metabolism (2907) 2907
peptides (2628) 2628
female (2449) 2449
mice (2302) 2302
kinetics (1881) 1881
chemistry, organic (1822) 1822
pharmacology & pharmacy (1753) 1753
chemistry, multidisciplinary (1644) 1644
dipeptide (1448) 1448
proteins (1396) 1396
analysis (1371) 1371
models, molecular (1314) 1314
amino acid sequence (1275) 1275
dipeptides - chemical synthesis (1233) 1233
chemistry, physical (1227) 1227
structure-activity relationship (1193) 1193
amino acids (1176) 1176
molecular structure (1149) 1149
chemistry (1146) 1146
research (1132) 1132
adult (1127) 1127
chemistry, medicinal (1111) 1111
dipeptides - therapeutic use (1075) 1075
amino-acids (1072) 1072
hydrogen-ion concentration (1009) 1009
protein conformation (1008) 1008
molecular sequence data (991) 991
middle aged (969) 969
stereoisomerism (956) 956
muramyl dipeptide (954) 954
neurosciences (909) 909
cells, cultured (875) 875
dose-response relationship, drug (861) 861
cell biology (841) 841
time factors (834) 834
hydrolysis (829) 829
dipeptides - administration & dosage (809) 809
in vitro techniques (805) 805
expression (799) 799
derivatives (774) 774
article (768) 768
magnetic resonance spectroscopy (754) 754
immunology (745) 745
dipeptides - analysis (726) 726
biophysics (709) 709
binding sites (706) 706
chemistry, analytical (686) 686
peptides - chemistry (677) 677
activation (661) 661
microbiology (660) 660
substrate specificity (660) 660
aged (638) 638
thermodynamics (636) 636
molecular conformation (610) 610
rats, sprague-dawley (600) 600
hydrogen bonding (591) 591
protein (590) 590
protein binding (584) 584
ligands (570) 570
enzymes (569) 569
cell line (566) 566
design (565) 565
research article (544) 544
peptide (541) 541
physiological aspects (541) 541
glycine (540) 540
inhibitors (537) 537
cells (532) 532
chromatography, high pressure liquid (529) 529
biochemical research methods (527) 527
spectroscopy (519) 519
identification (515) 515
chemical phenomena (511) 511
chemical properties (507) 507
rats, wistar (507) 507
mice, inbred c57bl (506) 506
rats, inbred strains (506) 506
biotechnology & applied microbiology (504) 504
cell line, tumor (503) 503
rabbits (490) 490
protease inhibitors - pharmacology (489) 489
apoptosis (487) 487
catalysis (487) 487
binding (475) 475
medicine, research & experimental (474) 474
physics, atomic, molecular & chemical (474) 474
amino acids - chemistry (468) 468
metabolism (463) 463
oligopeptides - chemistry (458) 458
enzyme inhibitors - pharmacology (457) 457
temperature (457) 457
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (21918) 21918
Russian (448) 448
German (179) 179
Chinese (171) 171
Japanese (169) 169
French (90) 90
Polish (16) 16
Spanish (14) 14
Italian (13) 13
Portuguese (13) 13
Czech (12) 12
Ukrainian (11) 11
Hungarian (7) 7
Korean (6) 6
Danish (5) 5
Swedish (4) 4
Norwegian (3) 3
Romanian (3) 3
Turkish (2) 2
Arabic (1) 1
Bulgarian (1) 1
Croatian (1) 1
Malay (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 2011, Volume 50, Issue 4, pp. 253 - 265
Background and Objective: Patients with type 2 diabetes mellitus often have impaired renal function or may have impaired hepatic function, which can pose... 
Research-and-development | Antihyperglycaemics, pharmacokinetics | Type-2-diabetes-mellitus | Diabetes-mellitus | Dipeptides, pharmacokinetics | Renal-impairment | Saxagliptin, pharmacokinetics | Haemodialysis | Liver-dysfunction | METFORMIN | THERAPY | CHRONIC LIVER-DISEASE | SAFETY | IMPROVES GLYCEMIC CONTROL | RISK | PHARMACOLOGY & PHARMACY | RANDOMIZED CONTROLLED-TRIAL | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Hepatic Insufficiency - urine | Dipeptides - pharmacokinetics | Humans | Middle Aged | Hypoglycemic Agents - analysis | Half-Life | Dipeptides - urine | Male | Metabolic Clearance Rate | Adamantane - urine | Adamantane - analysis | Adamantane - blood | Adult | Dipeptidyl-Peptidase IV Inhibitors - analysis | Female | Renal Insufficiency - blood | Hepatic Insufficiency - metabolism | Adamantane - pharmacokinetics | Adamantane - adverse effects | Adamantane - analogs & derivatives | Severity of Illness Index | Hypoglycemic Agents - pharmacokinetics | Dialysis Solutions - chemistry | Dipeptides - adverse effects | Dipeptides - analysis | Renal Insufficiency - metabolism | Renal Insufficiency - urine | Hepatic Insufficiency - blood | Kidney Failure, Chronic - metabolism | Kidney Failure, Chronic - therapy | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Kidney Failure, Chronic - blood | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Dipeptides - blood | Renal Dialysis | Complications and side effects | Liver diseases | Physiological aspects | Dosage and administration | Research | Pharmacokinetics | Saxagliptin
Journal Article
Cell, ISSN 0092-8674, 10/2016, Volume 167, Issue 3, pp. 774 - 788.e17
Journal Article
Journal Article
Diabetes Care, ISSN 0149-5992, 09/2009, Volume 32, Issue 9, pp. 1649 - 1655
The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone Ralph A.... 
ORAL GLUCOSE-TOLERANCE | POTENT | MONOTHERAPY | GLUCAGON-LIKE PEPTIDE-1 | GLYCEMIC DURABILITY | INSULIN-RESISTANCE | ENDOCRINOLOGY & METABOLISM | SECRETION | MELLITUS | INHIBITOR | Metformin - therapeutic use | Humans | Middle Aged | Male | Metformin - adverse effects | Young Adult | Hypoglycemic Agents - administration & dosage | Adamantane - therapeutic use | Placebos | Adult | Female | Metformin - administration & dosage | Adamantane - administration & dosage | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Adamantane - pharmacology | Dipeptides - therapeutic use | Double-Blind Method | Dipeptides - adverse effects | Dipeptides - pharmacology | Metformin - pharmacology | Treatment Outcome | Hypoglycemic Agents - pharmacology | Blood Glucose - drug effects | Dipeptides - administration & dosage | Adolescent | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Diabetics | Medical research | Care and treatment | Medicine, Experimental | Glucose | Pharmaceutical industry | Dextrose | Diabetes therapy | Heart failure | Physical examinations | Drug abuse | Substance abuse treatment | Research methodology | Patient care planning | Diabetes | Safety | Drug therapy | Hypoglycemia | Apoptosis | Index Medicus | Original Research
Journal Article
Organic & Biomolecular Chemistry, ISSN 1477-0520, 2015, Volume 13, Issue 35, pp. 9206 - 9213
The conformational behaviour of Ac-Ala-NHMe was studied in the gas-phase and in solution by theoretical calculations (B3LYP-D3/aug-cc-pVDZ level) and... 
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2013, Volume 369, Issue 14, pp. 1317 - 1326
Saxagliptin, a new oral antihyperglycemic drug in the DPP-4 inhibitor class, had no effect on the risk of cardiovascular events in patients with type 2... 
ALL-CAUSE | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | EVENTS | GLUCOSE CONTROL | MICROALBUMINURIA | DISEASE | CLINICAL-USE | PREVENTION | RISK | DEATH | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Adamantane - therapeutic use | Aged, 80 and over | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Hypoglycemia - chemically induced | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Dipeptides - therapeutic use | Double-Blind Method | Pancreatitis - epidemiology | Dipeptides - adverse effects | Kaplan-Meier Estimate | Pancreatitis - chemically induced | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Patient outcomes | Dosage and administration | Drug therapy | Heart diseases | Risk factors | Saxagliptin | Myocardial infarction | Cerebral infarction | Heart attacks | Peptidase | Diabetes mellitus | Pancreatitis | Cardiovascular disease | Angina | Patients | Heart rate | Ischemia | Diabetes | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent)
Journal Article